Ramaprasad P, Fernando A, Madhale S, Rao J R, Edward V K, Samson P D, Klatser P R, de Wit M Y, Smith W C, Cree I A
Stanley Browne Laboratories, Richardson Leprosy Hospital, Miraj, India.
Lepr Rev. 1997 Dec;68(4):301-15. doi: 10.5935/0305-7518.19970038.
Recent advances in treatment have achieved a large drop in the prevalence of active leprosy cases, but the incidence is at best decreasing slowly. Most people within leprosy-endemic populations have been exposed to Mycobacterium leprae, but few develop disease and it seems likely that the majority of the population develops protective immunity. If the site of initial infection is in the nose, dissemination of bacilli around the body to skin and nerve implies that the initial infection is bacilliferous and it has been shown that nasal M. leprae are detectable by polymerase chain reaction (PCR) of nasal swabs. Since salivary anti-M. leprae IgA (sMLIgA) levels are correlated with protection, we have surveyed groups of leprosy patients, contacts and the general population for both their sMLIgA and nasal PCR positivity. A total of 304 subjects were enrolled in the study: PCR and mucosal challenge tests were performed in 204 of these individuals. sMLIgA was present in 66% of treated patients, 76% of leprosy workers and 72% of healthy contacts. However, only 33% of indigenous subjects were sMLIgA+, in contrast to the earlier studies showing 74% positivity. PCR for M. leprae was present in both household contacts (2%) and indigenous controls (5%). In a subsequent follow-up study, nasal swabs were taken from 97 of those studied in the first series: three PCR+ individuals followed up after one year became negative, while of the remaining 94 PCR- individuals retested, 2 became positive. Of 112 subjects retested with the mucosal challenge test for sMLIgA: 22 converted from positive to negative and 12 from negative to positive. These results suggest that there is widespread subclinical transmission of M. leprae with transient infection of the nose resulting in the development of a mucosal immune response, despite the fact that few individuals will develop clinical disease. This may explain the current lack of effect of multidrug therapy (MDT) control programmes on incidence, although the reduction in general population immunity is consistent with some effect of MDT on transmission.
近年来治疗方法的进展使活动性麻风病例的患病率大幅下降,但发病率充其量只是在缓慢下降。麻风病流行地区的大多数人都接触过麻风分枝杆菌,但很少有人发病,而且大多数人似乎都产生了保护性免疫。如果初始感染部位在鼻子,杆菌在体内扩散到皮肤和神经意味着初始感染是带菌的,并且已经表明通过鼻拭子的聚合酶链反应(PCR)可以检测到鼻内的麻风分枝杆菌。由于唾液抗麻风分枝杆菌IgA(sMLIgA)水平与保护作用相关,我们对麻风病患者、接触者和普通人群进行了调查,检测他们的sMLIgA和鼻PCR阳性情况。共有304名受试者参与了这项研究:其中204人进行了PCR和黏膜激发试验。66%的接受治疗患者、76%的麻风病防治工作者和72%的健康接触者体内存在sMLIgA。然而,只有33%的本地受试者sMLIgA呈阳性,这与早期研究显示的74%阳性率形成对比。家庭接触者(2%)和本地对照者(5%)的麻风分枝杆菌PCR检测呈阳性。在随后的一项随访研究中,从第一项研究中的97名受试者采集了鼻拭子:1年后随访的3名PCR阳性个体转为阴性,而其余94名再次检测的PCR阴性个体中有2名转为阳性。在112名再次进行sMLIgA黏膜激发试验的受试者中:22人从阳性转为阴性,12人从阴性转为阳性。这些结果表明,麻风分枝杆菌存在广泛的亚临床传播,鼻子短暂感染会导致黏膜免疫反应的产生,尽管很少有人会发展为临床疾病。这可能解释了目前多药联合治疗(MDT)控制项目对发病率缺乏效果的原因,尽管普通人群免疫力的降低与MDT对传播的某种影响是一致的。